Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CONTAK RENEWAL 3 AVT · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| CONTAK RENEWAL 3 AVT | DEVICE | CONTAK RENEWAL 3 AVT |
Inclusion Criteria: Patients who meet the following criteria should be given consideration for inclusion in the clinical investigation: * Meet all device indications and contraindications * Willing and capable of providing informed consent, undergoing a device implant, participating in all testing...
Top 20 of 31 competitors
CONTAK RENEWAL 3 AVT is a cardiac device used for heart failure, specifically in patients with atrial fibrillation. It was studied in a Phase 3 clinical trial for these conditions. The device is intended to treat heart failure in this patient population.
CONTAK RENEWAL 3 AVT is developed by Boston Scientific Corporation, a medical device company traded on the New York Stock Exchange under the ticker symbol BSX. Boston Scientific is the developer of this cardiac device for heart failure.
CONTAK RENEWAL 3 AVT is in Phase 3 clinical development. The Phase 3 trial, identified as NCT00158977, has been completed. This device is investigational and not yet approved for commercial use.
CONTAK RENEWAL 3 AVT has one completed Phase 3 clinical trial, registered as NCT00158977. The trial enrolled 73 participants with heart failure and atrial fibrillation in the United States. It was an uncontrolled, non-randomized study that has been completed.
CONTAK RENEWAL 3 AVT is a specific model within the CONTAK RENEWAL 3 family of cardiac devices. The AVT designation indicates it is designed for patients with atrial fibrillation. It is a distinct version of the device tailored for this indication.